Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
View Patent ↗This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
1. An isolated antibody, or antigen-binding fragment thereof, that specifically binds an epitope of a Botulinum neurotoxin type A (BoNT/A), wherein the antibody or antigen-binding fragment comprises:
a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:107;
b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:109;
c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:142; and
d) VL CDRs comprising:
i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:177;
ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:179; and
ii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:212;
or
i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:181;
ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:183; and
ii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:215.
2. The isolated antibody of claim 1 , wherein said antibody comprises a light chain variable region (VL) comprising complementarity determining regions comprising the amino acid sequences of VL CDR1 (SEQ ID NO:177), VL CDR2 (SEQ ID NO:179), and VL CDR3 (SEQ ID NO: 212).
3. The isolated antibody or antigen-binding fragment of claim 1 , wherein said antibody comprises a light chain variable region (VL) comprising complementarity determining regions comprising the amino acid sequences of VL CDR1 (SEQ ID NO:181), VL CDR2 (SEQ ID NO:183), and VL CDR3 (SEQ ID NO: 215).
4. The isolated antibody or antigen-binding fragment of claim 1 , wherein said antibody is a human antibody or a humanized antibody.
5. The isolated antibody or antigen-binding fragment of claim 1 , wherein said antibody is a single chain Fv (scFv).
6. The isolated antibody or antigen-binding fragment of claim 1 , wherein said antibody is an IgG.
7. The isolated antibody or antigen-binding fragment of claim 1 , wherein said antibody is a Fab.
8. The isolated antibody or antigen-binding fragment of claim 1 , wherein said antibody is a (Fab′) 2 .
9. The isolated antibody or antigen-binding fragment of claim 1 , wherein said antibody is a (scFv′) 2 .
10. The isolated antibody or antigen-binding fragment of claim 1 , wherein said antibody or antigen-binding fragment comprises a full length heavy chain comprising:
a) a FR1 comprising an amino acid sequence of SEQ ID NO: 110;
b) a FR2 comprising an amino acid sequence of SEQ ID NO: 112;
c) a FR3 comprising an amino acid sequence of SEQ ID NO: 144; and
d) a FR4 comprising an amino acid sequence of SEQ ID NO: 146.
11. The isolated antibody or antigen-binding fragment of claim 3 , wherein said antibody or antigen-binding fragment comprises a full length light chain comprising:
a) a FR1 comprising an amino acid sequence of SEQ ID NO: 180;
b) a FR2 comprising an amino acid sequence of SEQ ID NO: 182;
c) a FR3 comprising an amino acid sequence of SEQ ID NO: 214; and
d) a FR4 comprising an amino acid sequence of SEQ ID NO: 216.
12. The isolated antibody or antigen-binding fragment of claim 3 , wherein said antibody or antigen-binding fragment comprises a full length heavy chain comprising:
a) a FR1 comprising an amino acid sequence of SEQ ID NO: 110;
b) a FR2 comprising an amino acid sequence of SEQ ID NO: 112;
c) a FR3 comprising an amino acid sequence of SEQ ID NO: 144; and
d) a FR4 comprising an amino acid sequence of SEQ ID NO: 146;
and a full length light chain comprising:
a) a FR1 comprising an amino acid sequence of SEQ ID NO: 180;
b) a FR2 comprising an amino acid sequence of SEQ ID NO: 182;
c) a FR3 comprising an amino acid sequence of SEQ ID NO: 214; and
d) a FR4 comprising an amino acid sequence of SEQ ID NO: 216.
13. The isolated antibody or antigen-binding fragment of claim 12 , wherein said antibody or antigen-binding fragment is a scFv.
14. The isolated antibody of claim 1 , wherein the antibody comprises:
a heavy chain variable region (VH) comprising complementarity determining regions comprising the amino acid sequence of VH CDR1 (SEQ ID NO:107), VH CDR2 (SEQ ID NO:109), and VH CDR3 (SEQ ID NO: 142); and
a light chain variable region (VL) comprising complementarity determining regions comprising the amino acid sequence of VL CDR1 (SEQ ID NO:177), VL CDR2 (SEQ ID NO:179), and VL CDR3 (SEQ ID NO: 212).
15. A composition comprising a plurality of anti-botulinum neurotoxin antibodies, or antigen-binding fragments thereof, said plurality comprising antibodies or antigen-binding fragments specific for different epitopes of a botulinum neurotoxin, and wherein said plurality of antibodies or antigen-binding fragments comprises an antibody or antigen-binding fragment according to claim 1 .
16. An isolated antibody or antigen-binding fragment that specifically binds each of A1 and A2 subtypes of BoNT/A with a K d that is more than ten times tighter than an antibody or antigen-binding fragment that comprises
a heavy chain variable region (VH) comprising complementarity determining regions comprising the amino acid sequence of VH CDR1 (SEQ ID NO:107), VH CDR2 (SEQ ID NO:109), and VH CDR3 (SEQ ID NO: 142); and
a light chain variable region (VL) comprising complementarity determining regions comprising the amino acid sequence of VL CDR1 (SEQ ID NO:177), VL CDR2 (SEQ ID NO:179), and VL CDR3 (SEQ ID NO: 212).
17. The composition of claim 15 , wherein said plurality of antibodies or antigen-binding fragments comprises an antibody or antigen-binding fragment that comprises a VL CDR1 comprising SEQ ID NO:181, a VL CDR2 comprising SEQ ID NO:183, and a VL CDR3 comprising SEQ ID NO: 215.
18. A method of binding Botulinum neurotoxin (BoNT) in a mammal, said method comprising administering to said mammal an antibody, or an antigen-binding fragment thereof, comprising:
a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:107;
b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:109;
c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:142; and
d) VL CDRs comprising:
i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:177;
ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:179; and
ii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:212;
or
i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:181;
ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:183; and
ii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:215.
19. The method of claim 18 , wherein said antibody or antigen-binding fragment comprises:
i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:177;
ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:179; and
ii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:212.
20. The method of claim 18 , wherein said antibody or antigen-binding fragment comprises:
i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:181;
ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:183; and
ii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:215.
21. A method of detecting a Botulinum neurotoxin (BoNT) in a biological sample, the method comprising:
a) contacting the biological sample with the isolated antibody, or an antigen-binding fragment thereof, of claim 1 ; and
b) detecting binding, if any, of the antibody to an epitope present in the sample.